Industry Consolidation: Role of Compliance in Mergers, Acquisitions, and Divestitures
|
|
- Harold Perry
- 5 years ago
- Views:
Transcription
1 Industry Consolidation: Role of Compliance in Mergers, Acquisitions, and Divestitures Prepared for CBI s Pharmaceutical Compliance Congress April 28, 2017
2 M&A Activity in the Pharmaceutical Industry THE TREND TOWARD INDUSTRY CONSOLIDATION Over the past two decades, M&A activity within the pharmaceutical industry has been prolific. In fact, when examining deals valued at more than $1 billion, the results are shocking Since 1995, 60 pharma companies have, through acquisitions and mergers, consolidated into only 10 companies! 2
3 M&A Activity in the Pharmaceutical Industry THE TREND TOWARD INDUSTRY CONSOLIDATION 3
4 M&A Activity in the Pharmaceutical Industry THE TREND TOWARD INDUSTRY CONSOLIDATION RECENT ACTIVITY 4
5 M&A Activity in the Pharmaceutical Industry TYPES OF ACQUISITIONS 1. Horizontal: Acquisition of companies that have a high quality product line and are trading in markets where the acquirer is also present Allows for improved cash flow Tend to be more profitable if new products are acquired AND new territories are entered 2. Vertical: Acquisition of companies to enrich the lifecycle of existing products Integration: Acquisition of a biotech company to obtain enabling technologies or enrich one s one R&D pipeline Extension: Acquisition of a generics company to protect one s own products when patents expire OTC Switch: Acquisition of an over-the-counter company to switch one s prescription products to the OTC field 5
6 M&A Activity in the Pharmaceutical Industry THE TREND TOWARD INDUSTRY CONSOLIDATION M&A activity within the pharmaceutical industry is likely to trend upwards in 2017 and beyond but why? Rising costs and risks of drug development Diminishing conversion levels Influence of managed care Attempts to limit eligibility for patients Increased competition due to generics and biosimilars Increased demand for new drugs due to aging demographics and global population increases Increased purchase power due to more divestitures of non-core assets Additionally, the Trump Administration s pledge to allow companies to repatriate at a lower tax rate could encourage even more industry consolidation! 6
7 Pre-Acquisition Due Diligence Due Diligence Objectives High Risk Areas Prioritizing Risks Assessing Risks Making Due Diligence Decisions
8 Pre-Acquisition Due Diligence DUE DILIGENCE OBJECTIVES What IS due diligence? The process of identifying and evaluating the information and issues material to achieving a pharmaceutical company s objectives in the sale or purchase or a business or asset group. What are we trying to achieve when conducting due diligence? Understand the business of the target Discover red flags (i.e., hidden/unexpected liabilities and risks) Determine whether those red flags go to value or illegality such that a company does not want to go forward with the deal Inform the company s post-acquisition work plan from an operational standpoint 8
9 Pre-Acquisition Due Diligence HIGH RISK AREAS As an initial matter, it is important to understand the areas in which the government is most actively attempting to develop and pursue claims against companies within the pharmaceutical industry: Foreign Corrupt Practices Act ( FCPA ) Anti-Kickback Statute ( AKS ) o o HCP Speaker Programs and Meals Research Programs and Travel o Rebates False Claims Act ( FCA ) o o Off-Label Promotion False and Misleading Marketing and Labelling Ex-US Third Party Risk Overseas The potential harm caused by these risks is largely informed by the target company s business model, the countries in which it operates, and the robustness of the company s existing Compliance Program. 9
10 Pre-Acquisition Due Diligence HIGH RISK AREAS FCPA 2016: Andrew Weismann, Chief of the Fraud Section DOJ Criminal Division, emphasized the DOJ s dedication to enforcing the FCPA. The DOJ is committed to enhancing its efforts to detect and prosecute both individuals and companies for violations of the FCPA, which criminalizes various acts of bribery Memorandum from Andrew Wiessmann (April 5, 2016) Since then, the DOJ has utilized increased enforcement resources and coordinated with foreign counterparts to successfully bring high-profile actions against violators, making it increasingly important to review the target company s interactions with ex-us third parties. AstraZeneca: Paid more a $5m penalty related to improper payments made by subsidiaries to Chinese and Russian officials GlaxoSmithKline: Paid a $20m penalty when its China-based subsidiaries engaged in pay-to-prescribe schemes to increase sales Teva: Paid a $519m penalty related to bribes to officials in Russia, Ukraine, and Mexico 10
11 Pre-Acquisition Due Diligence HIGH RISK AREAS FRAUD As with anti-bribery enforcement, the DOJ has made it clear that fighting healthcare fraud is one of its top priorities. Additionally, the high return on investment in healthcare enforcement contributes to the DOJ s focus currently, the federal government recovers eight dollars for every dollar invested! Certain activities undertaken by pharma companies are more heavily policed than others, resulting in claims under the AKS and FCA: Prior Authorizations: Warner Chilcott paid a $125m fine related to paying kickbacks to HCPs to manipulate prior authorizations to induce insurance companies to pay for prescriptions of one of their products Clinical Trial Data: GSK paid a $3b fine related to, among other allegations, preparing, publishing, and distributing a misleading medical journal article that misreported that a clinical trial of a product demonstrated efficacy in the treatment of depression in patients under age 18, when the study failed to demonstrate efficacy Rebates: Novartis paid a $380m fine related to the provision of rebates to specialty pharmacies as inducements to increase the pharmacies prescription of their products 11
12 Pre-Acquisition Due Diligence PRIORITIZING & ASSESSING RISK Once the acquirer understands which activities the government most closely scrutinizes in the pharmaceutical industry, one must determine the risk profile of the target company in relation to those high risk activities and plan accordingly but how? In a perfect world, the acquirer should conduct an enterprise-wide analysis, including a full assessment of the target company s compliance program and a corresponding audit, which would involve: 1. Identify Risks through an enterprise-wide Risk Assessment; 2. Rank Risks based on managed risks identified in the Assessment; 3. Perform Audit of both compliance and operational risks by reviewing policies, conducting interviews with risk owners, and testing existing controls; and 4. Evaluate Findings and Identify Gaps within the context of existing policies and applicable external standards. 12
13 Pre-Acquisition Due Diligence PRIORITIZING & ASSESSING RISK The tools used to conduct the enterprise-wise analysis (in a perfect world!) may look like this: Compliance Risk Assessment Template Enterprise Wide Model 13
14 Pre-Acquisition Due Diligence PRIORITIZING & ASSESSING RISK Business Unit Evaluation Template 14
15 Pre-Acquisition Due Diligence PRIORITIZING & ASSESSING RISK Business Activity Risk Assessment Evaluation Key 15
16 Pre-Acquisition Due Diligence PRIORITIZING & ASSESSING RISK Unfortunately, we do not live in a perfect world! Here s the reality: Deals in the pharmaceutical industry move quickly and urgent deadlines are common, making it nearly impossible to conduct a full assessment of a target company. Therefore, in order to uncover any potential deal-breakers, the acquirer must conduct focused, thorough, and often costly due diligence but how? 1. Plan, Plan, Plan: Given the target company s business model and the countries in which it operates, prepare a detailed work plan to identify the activities that would pose the most frequent and severe risks. 2. Perform Limited Analysis: Pull samples of documentation related the highest risk activities (e.g., Open Payments data, invoices from HCPs, promotional materials) and analyze. 3. Identify Red Flags: Drawing informed conclusions from the limited samples examined, identify, and rate any potential red flags based on materiality to the underlying deal. 16
17 Pre-Acquisition Due Diligence PRIORITIZING & ASSESSING RISK There is no one-size-fits-all solution to conducting pre-acquisition due diligence. Therefore, an acquirer s plan of attack should be specifically tailored to risk profile of the target company. For example: Does the target have marketed products? Pull the target s publicly-available Open Payments data and cross-reference against its top prescribers is there a positive correlation? What are the target company s Key Opinion Leaders doing? o Do the marketed products include specialty drugs? Take a closer look at reimbursement mechanisms, clinical trial data, drug prices, etc. If there are no marketed products, what is happening in the R&D pipeline? Assess clinical trials and independent studies who is conducting them? If the target company is foreign, it most likely does not maintain a robust body of policies what do you assess? Because 90% of overseas risk is created by third parties, vet engagements with HCPs, researchers, distributors, and government officials. 17
18 Pre-Acquisition Due Diligence PRIORITIZING & ASSESSING RISK CASE STUDY Your company is deciding whether to acquire a privately-owned pharmaceutical company based in Mexico that has a number of products on the market and a robust R&D function. You are managing the due diligence process, and you have a short timeline to report back with your findings. What are the top three risk areas you will look at? What kind of activities expose this target to the most risk? How will you properly vet those activities to ensure any bona fide red flags are identified? 18
19 Pre-Acquisition Due Diligence MAKING DECISIONS BASED ON DUE DILIGENCE Upon completion of the due diligence process, an acquirer is often left with a number of red flags and must then determine whether any constitute a deal-breaker. It is important to remember that red flags will need to be defended to the potential buyer, so ensure that all red flags are bona fide to maintain credibility. Also keep in mind that even where bona fide red flags exist, there are a number of potential outcomes to consider: 1. Re-evaluation of investment, price, or return 2. Re-negotiation of key terms/contractual language or introduction of new terms 3. Amendment of regulatory strategy 4. Abandonment of the transaction 19
20 Post-Acquisition Integration Integration Challenges Integration Activities Panel Discussion: Prioritizing Integration Activities Structuring Integration Plan Executing Integration Plan
21 Post-Acquisition Integration INTEGRATION CHALLENGES Soyou ve closed the deal! But what now? While every deal is different, there are certain common postacquisition challenges that arise when preparing to integrate the target company into your own: Limited pre-deal transparency Different company culture Workforce transition Different or inconsistent policies Separate or incompatible systems Cybersecurity measures Customer Retention Successor liability 21
22 Post-Acquisition Integration INTEGRATION ACTIVITIES The first days after an acquisition are crucial. It is important to hit the ground running with a work plan informed by the pre-acquisition due diligence process but how? Verify due diligence data. Gather additional information. Prioritize Activities. Implement! Establish integration teams. Adjust work plan accordingly. 22
23 Post-Acquisition Integration PANEL DISCUSSION TOPIC OVERVIEW Integration Activity Prioritization Integration Plan Structure Integration Plan Implementation 23
24 Contact Information Ed Buthusiem Managing Director, BRG Sarah Chopp Senior Corporate Counsel, Pfizer Philip Munkacsy Senior Director Corporate Compliance, Impax Labs
I nsurance brokers and investment banks have at
Securities Regulation & Law Report Reproduced with permission from Securities Regulation & Law Report, 44 SRLR 1030, 05/12/2012. Copyright 2012 by The Bureau of National Affairs, Inc. (800-372-1033) http://www.bna.com
More informationInsert Slide Title. Jennifer A. Romanski, Esq. February 8, 2017
Insert Slide Title Jennifer A. Romanski, Esq. February 8, 2017 Interactions/Engagements with Healthcare Professionals (HCPs) and Healthcare Organizations (HCOs) Consulting Payments Service Arrangements
More informationCOMPLIANCE WITH PATIENT ASSISTANCE PROGRAMS AND CO-PAY CARDS. Judd Katz JD MHA November 2016
COMPLIANCE WITH PATIENT ASSISTANCE PROGRAMS AND CO-PAY CARDS Judd Katz JD MHA November 2016 Background information Patient Assistance Programs Copay Cards/Assistance Programs Reimbursement Support AGENDA
More informationA Special Type of Government Scrutiny: Pharmaceutical Manufacturer Relationships with Specialty Pharmacies: Part II
April 2017 Follow @Paul_Hastings A Special Type of Government Scrutiny: Pharmaceutical Manufacturer Relationships with Specialty Pharmacies: Part II By Gary F. Giampetruzzi & Jonathan Stevens Reproduced
More informationHigh Risk Markets & FCPA
High Risk Markets & FCPA SCCE SoCal Regional Compliance & Ethics Conference January 26, 2018 Brian R. Michael Partner King & Spalding LLP Julie Myers Wood Chief Executive Officer Guidepost Solutions Tedra
More informationContracting with Specialty Pharmacies and Hubs 17 th Annual Pharma and Medical Device Compliance Congress. October 20, 2016
Contracting with Specialty Pharmacies and Hubs 17 th Annual Pharma and Medical Device Compliance Congress October 20, 2016 Thomas Beimers Hogan Lovells Thomas.beimers@hoganlovells.com Sarah Franklin Covington
More informationSEC FCPA Action Against Bristol-Myers Squibb Highlights Importance of Addressing Red Flags and Compliance Gaps
October 8, 2015 SEC FCPA Action Against Bristol-Myers Squibb Highlights Importance of Addressing Red Flags and Compliance Gaps Executive Summary On October 5, 2015 the U.S. Securities and Exchange Commission
More informationThe Perils Of Pharma: The Pharmaceutical Industry And The FCPA
W O R L D - C H E C K W H I T E P A P E R The Perils Of Pharma: The Pharmaceutical Industry And The FCPA by Michael Osajda Statement of intent In recent years, the pharmaceutical industry has been subjected
More informationPETCO INTERNATIONAL, LLC FOREIGN CORRUPT PRACTICES ACT AND ANTI-BRIBERY POLICY. Effective: January 1, 2012
PETCO INTERNATIONAL, LLC FOREIGN CORRUPT PRACTICES ACT AND ANTI-BRIBERY POLICY Effective: January 1, 2012 ( PETCO ) must comply with all anti-bribery laws, including the U.S. Foreign Corrupt Practices
More informationGlobal Policy on Anti-Bribery and Anti-Corruption
1 Global Policy on Anti-Bribery and Anti-Corruption OUR GLOBAL POLICY ON ANTI-BRIBERY AND ANTI-CORRUPTION Did You know?? PolyOne is committed to the prevention, deterrence and detection of fraud, bribery
More informationHEATHER I. BATES Managing Director, BRG Health Analytics. BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, 2 nd Floor Washington, DC 20036
Curriculum Vitae HEATHER I. BATES Managing Director, BRG Health Analytics BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, 2 nd Floor Washington, DC 20036 Direct: 202.480.2660 Cell: 202.641.1035 hbates@thinkbrg.com
More informationAmgen GLOBAL CORPORATE COMPLIANCE POLICY
1. Scope Applicable to all Amgen Inc. and subsidiary or affiliated company staff members, consultants, contract workers, secondees and temporary staff worldwide ( Covered Persons ). Consultants, contract
More informationCORPORATE COMPLIANCE PROGRAM AND ENHANCED COMPLIANCE OBLIGATIONS
I. CORPORATE COMPLIANCE PROGRAM 1. A clearly articulated corporate policy against violations of the FCPA, including its anti-bribery, books and records, and internal controls provisions, and other applicable
More informationCompliance. TODAY March Meet Donna Abbondandolo
Compliance TODAY March 2013 a publication of the health care compliance association www.hcca-info.org Meet Donna Abbondandolo Director of Compliance, Internal Audit & Compliance, Catholic Health Services
More informationBribery and Corruption
Bribery and Corruption The FCPA, UK Bribery Act, and Other Anti-Corruption Measures 2018 Association of Certified Fraud Examiners, Inc. Introduction The FCPA and the UK Bribery Act are the two premier
More informationPANGAEA LOGISTICS SOLUTIONS, LTD. ANTI-CORRUPTION COMPLIANCE POLICY
PANGAEA LOGISTICS SOLUTIONS, LTD. ANTI-CORRUPTION COMPLIANCE POLICY I. INTRODUCTION It is the policy of Pangaea Logistics Solutions, Ltd. and its subsidiaries (collectively, the Company ) to ensure that
More informationProtecting Your Company and Executives from FCPA Liability in Jonathan T. Cain Aaron M. Tidman
Protecting Your Company and Executives from FCPA Liability in 2013 June 20, 2013 Paul E. Pelletier Jonathan T. Cain Aaron M. Tidman 1 FCPA Is Focus of U.S. Government Combating corruption [is] one of the
More informationFrom the Office Suite to Cell Block C: Potential Criminal and Regulatory Implications of Pharma/Biotech/Device Products Liability Lawsuits
From the Office Suite to Cell Block C: Potential Criminal and Regulatory Implications of Pharma/Biotech/Device Products Liability Lawsuits BUTLER SNOW 1 UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT
More informationANTI-BRIBERY POLICY STATEMENT
ANTI-BRIBERY POLICY STATEMENT 1. BACKGROUND AND PURPOSE Department 13 (D13) maintains an Anti-Bribery Policy prohibiting any improper or unethical payment to government officials or a party to a private
More informationCARDAX, INC. FOREIGN CORRUPT PRACTICES ACT COMPLIANCE POLICY
CARDAX, INC. FOREIGN CORRUPT PRACTICES ACT COMPLIANCE POLICY Purpose The purpose of this Foreign Corrupt Practices Act Compliance Policy (this Policy ) is to help ensure compliance by Cardax, Inc. (the
More informationTrack III-A. Creating Relationships with Prescription Drug Plans and Managed Care Organizations
Track III-A Creating Relationships with Prescription Drug Plans and Managed Care Organizations David L. Ralston Legal Director Schering-Plough Corporation Part D is for Dollars Follow the money by tracing
More informationIndustry Funding of Continuing Medical Education
Industry Funding of Continuing Medical Education June 25, 2010 Julie K. Taitsman, M.D., J.D. Chief Medical Officer, Office of Inspector General U.S. Department of Health and Human Services Financial Relationships
More informationFraud in the Pharmaceutical Industry
Fraud in the Pharmaceutical Industry The United States qui tam Whistleblower Law Getnick & Getnick LLP Counsellors At Law Rockefeller Center, 620 Fifth Avenue New York, NY 10020 Phone: (212) 376-5666 Fax:
More informationCode on Global Interactions. with Healthcare Professionals
Code on Global Interactions with Healthcare Professionals 2 Table of Contents Introduction... 5 Anti-Bribery Anti-Corruption... 6 Guiding Principles... 7 Promotional Activities... 8 Healthcare Professionals
More informationAnti-Bribery and Corruption Policy
Introduction Crawford & Company and all of its subsidiaries throughout the world ( Crawford or the Company ) acts ethically and complies with all anticorruption laws, including the United States Foreign
More informationThe FCPA and the Pharmaceutical Industry
The FCPA and the Pharmaceutical Industry Kelly A. Moore Mark A. Srere Alison Tanchyk Dante September 14, 2010 www.morganlewis.com Today s Presenters Kelly A. Moore New York Mark Srere Washington, D.C.
More informationHidden Business Risks in Russia June 16, 2016
Hidden Business Risks in Russia June 16, 2016 Tom Engelhart & Derek Harris www.kreller.com 1.800.444.6361 Kreller Background Comprehensive international due diligence and compliance services since 1988.
More informationForeign Corrupt Practices Act Policy
Policy Message from the CEO At SAExploration, we place a high value on honesty and integrity as well as delivering quality service to our customers. Our core values and commitment to high ethical standards
More informationDEVELOPMENTS IN THE PRESCRIPTION DRUG MARKET: OVERSIGHT. Before the Full House Committee on Oversight and Government Reform.
Statement for the record: DEVELOPMENTS IN THE PRESCRIPTION DRUG MARKET: OVERSIGHT Before the Full House Committee on Oversight and Government Reform February 4, 2016 David A. Balto Law Offices of David
More informationSETTING A STANDARD FOR GP COMPLIANCE
SETTING A STANDARD FOR GP COMPLIANCE CURRENT LANDSCAPE AND WHAT DOES GP COMPLIANCE LOOK LIKE? MAY 9, 2017 2017 HURON CONSULTING GROUP INC. SPEAKER INTRODUCTIONS Clay Willis Director T 404-825-3319 E cwillis@huronconsultinggroup.com
More informationANTI-BRIBERY AND ANTI-CORRUPTION POLICY
ANTI-BRIBERY AND ANTI-CORRUPTION POLICY Amended to May 18, 2017 Prohibition against Giving Bribes to Third Parties including Government Officials Table of Contents Heading Page Number INTRODUCTION 2 PURPOSE
More informationPrevention Of Corruption
Prevention Of Corruption Global Compliance Table Of Contents Standards Application page 6 Purpose page 5 Scope page 6 Bribery/Improper Payments, page 8 Ethical Business Practices, page 8 Unfair Business
More informationLessons Learned from FCPA Cases in Healthcare
//07 Lessons Learned from FCPA Cases in Healthcare March 0, 07 PwC Sulaksh Shah, Partner Forensic Services, PwC Gerardo Salazar, Director Forensic Services, PwC What is the FCPA? The Foreign Corrupt Practices
More informationCALIX, INC. ANTI-BRIBERY COMPLIANCE POLICY
CALIX, INC. ANTI-BRIBERY COMPLIANCE POLICY 1.0 INTRODUCTION AND PURPOSE STATEMENT The Foreign Corrupt Practices Act ( FCPA ) is a US federal law that applies to both individuals and businesses. All Calix,
More informationGERALD (JERRY) LEWANDOWSKI. BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, Second Floor Washington, DC 20036
Curriculum Vitae GERALD (JERRY) LEWANDOWSKI BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, Second Floor Washington, DC 20036 Direct: 202.480.2643 Mobile: 202.258.2669 jlewandowski@thinkbrg.com Jerry Lewandowski
More informationForeign Corrupt Practices Act Policy August 16, 2017
I. PURPOSE To provide guidelines to all officers, directors, employees, consultants and agents that are employed by the Company to ensure compliance with the Foreign Corrupt Practices Act of the United
More informationCurrent Issues in Patient and Product Support. October 20, 2016
Current Issues in Patient and Product Support October 20, 2016 How Did a Perennial Issue Become the Hot Topic? 1. Reimbursement Support 2. Patient Assistance Programs 3. Donations to Charitable Foundations
More informationWILLBROS CORPORATE POLICY
PAGE NO. Page 2 of 9 Reporting Demands for a Bribe It is absolutely imperative that each and every person who does business with the Company understands that Company Representatives will not, under any
More informationAutomatic Data Processing, Inc. ADP Anti-Bribery Policy
Automatic Data Processing, Inc. ADP Anti-Bribery Policy Adopted August 2008 Revised November 17, 2009 and August 9, 2011 Statement by Chief Executive Officer AUTOMATIC DATA PROCESSING, INC. ANTI-BRIBERY
More informationFCPA Compliance. Conducting Due Diligence on Third Parties. November 10, 2015
FCPA Compliance Conducting Due Diligence on Third Parties November 10, 2015 Jesica Gilbert Director of Ethics and Compliance American Bureau of Shipping Elsa Manzanares, Marla Poirot, and Michelle Schulz
More informationGlossary of Definitions
Glossary of Definitions For purposes of MAPP, the terms listed below have the following meaning: Advisory Board: means a specific type of consultancy engagement where experts are engaged to offer advice
More informationFCPA. Due Diligence. The REPORT. The Importance of Pre-Merger Due Diligence
Due Diligence Critical Steps to Take and Questions to Ask When Conducting Pre-Merger Anti-Corruption Due Diligence By Michael J. Gilbert and Mauricio A. España, Dechert LLP There is no doubt that the most
More informationInstitute of Internal Auditors 2018 IIA CHICAGO CHAPTER JOIN NTAC:4UC-11
IIA CHICAGO CHAPTER JOIN US: @IIACHI UNDERSTANDING THE FCPA: RECENT TRENDS AND CONSIDERATIONS PRESENTED BY: ALI RAMPURAWALA, MANAGER MUMTA TANEJA, MANAGER AGENDA Overview of Foreign Corrupt Practices Act
More informationPreparing for the new age of global anti-corruption enforcement Presentation to WPACC. October 15, 2013
Preparing for the new age of global anti-corruption enforcement Presentation to WPACC October 15, 2013 Welcome Welcome and introductions 8:30am 8:45 am Robert T. Biskup Director, Deloitte Forensic Deloitte
More informationPotential Perils of Using New Media in Marketing and Promotion. Christina M. Markus (202)
Potential Perils of Using New Media in Marketing and Promotion Christina M. Markus (202) 626-2926 cmarkus@kslaw.com FACEBOOK Using Facebook to develop online community TWITTER Using Twitter as another
More informationAsia-Pac Anti-Corruption Update Roundtable. Panel discussion moderated by: Chris Fordham 14 September 2017
Asia-Pac Anti-Corruption Update Roundtable Panel discussion moderated by: Chris Fordham 14 September 2017 Panelists Chris Fordham (Moderator) Managing Partner, Asia Pacific, Fraud Investigation & Dispute
More informationForeign Corrupt Practices Act Policy
Foreign Corrupt Practices Act Policy Current as of April 1, 2015 IPM Headquarters 8401 Colesville Road, Suite 200 Silver Spring, MD 20910 USA Phone 1-301-608-2221 Fax 1-301-608-2241 www.ipmglobal.org Introduction
More informationThe False Claims Act. False Claims Act Basics (I)
The False Claims Act Basic Concepts, Recent Trends, and Strategies for Minimizing Risks Philip D. Robben February 26, 2013 False Claims Act Basics (I)! Imposes liability on those who submit false claims
More informationU.S. v. Sulzbach: Government Theories, Potential Defenses, and Lessons Learned
U.S. v. Sulzbach: Government Theories, Potential Defenses, and Lessons Learned Presented By: David O Brien Christine Rinn Michael Paddock HOOPS 2007 - Washington, DC October 15-16 Background June 1994:
More informationManufacturer Patient Support Initiatives: Current Practices and Recent Challenges. Andrew Ruskin Morgan Lewis
Intersecting Worlds of Drug, Device, Biologics and Health Law AHLA/FDLI May 22, 2012 Manufacturer Patient Support Initiatives: Current Practices and Recent Challenges by Andrew Ruskin Morgan Lewis The
More informationWright Medical Group N.V. Anti-Bribery Compliance Policy
Wright Medical Group N.V. Anti-Bribery Compliance Policy Title: Wright Medical Group N.V. Wright Anti-Bribery Compliance Policy Document Owner/Dept.: Tamara Tubin Corporate Compliance Effective Date: 17
More informationEFFECTIVE DATE: FEBRUARY 2006 REVISED: JULY 2011; AUGUST 2014
I. POLICY CBRE, Inc. and its worldwide subsidiaries (collectively, CBRE ) have adopted the following Policy with respect to all of their global commercial transactions. Oversight of this Policy and CBRE
More informationCBI PAP LEGAL UPDATE MEDICARE & MEDICAID A REVIEW OF COMPLIANCE WITH GOVERNMENT PROGRAMS. September 26, Sarah difrancesca Partner Cooley LLP
CBI PAP LEGAL UPDATE MEDICARE & MEDICAID A REVIEW OF COMPLIANCE WITH GOVERNMENT PROGRAMS September 26, 2017 Sarah difrancesca Partner Cooley LLP attorney advertisement Copyright Cooley LLP, 3175 Hanover
More informationAnti-Corruption Policy Global (Anti-Corruption Program - Global) CORPORATE LEGAL ETHICS & COMPLIANCE. Associate General Counsel - Compliance
CORPORATE LEGAL ETHICS & COMPLIANCE 100.102 Policy Owner: Anti-Corruption Policy Global (Anti-Corruption Program - Global) Associate General Counsel - Compliance Effective Date: 2015-Jun-17 Rev: 5 Page
More informationProduct Reimbursement Services and Patient Assistance Programs KATHY CHAURETTE ALESSANDRO MARTUSCELLI
Product Reimbursement Services and Patient Assistance Programs KATHY CHAURETTE ALESSANDRO MARTUSCELLI Overview of Legal Framework OIG Guidance Pharmaceutical manufacturers may provide certain support services
More informationEFFECTIVE DATE August 17, ISSUED BY: Compliance and Legal Department APPROVED BY: Board of Directors
Valeant Pharmaceuticals International, Inc. POLICY NO. H.R. Sec. 9 914 EFFECTIVE DATE August 17, 2016 PAGE NO. 1 of 9 SUBJECT: ISSUED BY: Compliance and Legal Department APPROVED BY: Board of Directors
More informationDEFICIT REDUCTION ACT AND FALSE CLAIMS POLICY INFORMATION FOR All NEW YORK WORKFORCE MEMBERS
DEFICIT REDUCTION ACT AND FALSE CLAIMS POLICY INFORMATION FOR All NEW YORK WORKFORCE MEMBERS The Company is committed to preventing health care fraud, waste and abuse and complying with applicable state
More informationThe Impact of the Fraud and Abuse Laws on Pharmaceutical Advertising and Marketing Compliance: A Manufacturer s Perspective
International In-house Counsel Journal Vol. 4, No. 13, Autumn 2010, 1 The Impact of the Fraud and Abuse Laws on Pharmaceutical Advertising and Marketing Compliance: A Manufacturer s Perspective LESLIE
More informationGENERAL GUIDANCE NOTE
BACKED BY SAMPLE POLICY Anti-Bribery Compliance GENERAL GUIDANCE NOTE This sample anti-bribery policy is generically illustrative, but is neither legal advice nor a substitute for consultation with knowledgeable
More informationRESPIRONICS, INC. CONTRACTING WITH HEALTHCARE PROFESSIONALS OR PROVIDERS AND REFERRAL SOURCES POLICY
Page 1 of 6 RESPIRONICS, INC. CONTRACTING WITH HEALTHCARE PROFESSIONALS OR PROVIDERS AND REFERRAL SOURCES POLICY I. Purpose This document sets forth Respironics, Inc. s ( Company ) policy for engaging
More informationFCPA Due Diligence in M&A Amid Increased Enforcement
Presenting a live 90-minute webinar with interactive Q&A FCPA Due Diligence in M&A Amid Increased Enforcement Developing and Risks and Implementing Post-Closing Protections WEDNESDAY, AUGUST 24, 2016 1pm
More informationConflicts of Interest 9/10/2017. Everything a Health Care Executive Needs to Know about the Anti-Kickback Statute. May 2, 2017 Article from JAMA:
Everything a Health Care Executive Needs to Know about the Anti-Kickback Statute Matthew Krueger Assistant United States Attorney E.D. of Wisconsin Stacy Gerber Ward von Briesen & Roper, S.C. Conflicts
More informationDocument Type Doc ID Status Version Page/Pages. Policy LDMS_001_ Effective of 11 Title: Global Policy on Ethical Interactions
Policy LDMS_001_00145767 Effective 6.0 1 of 11 AstraZeneca Owner Ageborg, Katarina Authors Shah, Himani Approvals Approval Reason Approver Date Reviewer Approval Shah, Himani 2015/04/10 13:40:28 Policy
More informationUnited States Department of Justice Foreign Corrupt Practices Act Initiative for Pharmaceutical and Medical Device Manufacturers
United States Department of Justice Foreign Corrupt Practices Act Initiative for Pharmaceutical and Medical Device Manufacturers The Tenth Annual Pharmaceutical Regulatory and Compliance Congress and Best
More informationEFFECTIVE DATE November 1, ISSUED BY: Compliance and Legal Department APPROVED BY: Board of Directors
Valeant Pharmaceuticals International, Inc. POLICY NO. H.R. Sec. 9 914 EFFECTIVE DATE November 1, 2013 PAGE NO. 1 of 9 SUBJECT: ISSUED BY: Compliance and Legal Department APPROVED BY: Board of Directors
More informationSOUTHWESTERN ENERGY COMPANY ANTI-CORRUPTION COMPLIANCE POLICY
SOUTHWESTERN ENERGY COMPANY ANTI-CORRUPTION COMPLIANCE POLICY I. Introduction At Southwestern Energy Company, we and our controlled subsidiaries and joint ventures (collectively, SWN or the Company ) build
More informationCompliance & Ethics. a publication of the society of corporate compliance and ethics JUNE 2018
Compliance & Ethics PROFESSIONAL corporatecompliance.org a publication of the society of corporate compliance and ethics JUNE 2018 Meet Thomas Topolski, CCEP-I Executive Vice President, Turner & Townsend
More informationSubject ANTI BRIBERY POLICY Section POLICY STATEMENT Sponsor CHIEF LEGAL OFFICER
Subject ANTI BRIBERY POLICY Section POLICY STATEMENT Sponsor CHIEF LEGAL OFFICER Number Version 1.0 Effective Date: December 2014 Anti Bribery Policy Indivior PLC, its subsidiaries and related companies
More informationKorea Compliance Update Asia Pacific Pharmaceutical Compliance Congress Mini Summit XIII SEPTEMBER 17, 2014
Korea Compliance Update Asia Pacific Pharmaceutical Compliance Congress Mini Summit XIII SEPTEMBER 17, 2014 Korea Update 2014 1. Legislation new sanction for violations 2. Enforcement still high priority
More informationThe Institute of Internal Auditors Detroit Chapter Presents
The Institute of Internal Auditors Detroit Chapter Presents 1 Understanding the FCPA & Recent Trends Presented by: Scott Stringer Director Baker Tilly Virchow Krause, LLP Mumta Taneja Manager Baker Tilly
More informationFraud, Bribery and Corruption Control Policy
Fraud, Bribery and Corruption Control Policy 1. Introduction DuluxGroup acknowledges the need for directors, executives, employees and contractors to observe the highest ethical standards of corporate
More informationAnti-Bribery and Anti-Corruption Policy
Anti-Bribery and Anti-Corruption Policy New Gold Inc. and its subsidiaries (together, New Gold, the Company, or we ) are committed to honest and ethical conduct. This theme is emphasized in our Code of
More informationUpdate. The authors of this article are all consultants with Huron Consulting Group, which serves the continuum of life sciences organizations
Life Science Compliance Update REPRINTED FROM U.S. EDITION Volume 2.1 February 2016 Your Special Relationships Specialty Pharmacies and 5 Thoughtful Controls to Consider public advocates, and the media
More informationGLOBAL ANTI-CORRUPTION POLICY
COMPANY POLICY Policy Title: Global Anti-Corruption Policy CMS Number: CMS-300-05-PL-00013 Policy Owner: Legal & Compliance Issuing Authority: Executive Vice President, Chief Legal Officer & Secretary
More informationPhysician Payments Sunshine Act Proposed Rule Published
Physician Payments Sunshine Act Proposed Rule Published Kim Kannensohn Krist Werling Holly Carnell www.mcguirewoods.com McGuireWoods news is intended to provide information of general interest to the public
More informationEstablishing an Anti-Corruption Compliance Program in Canada
PUBLICATION Establishing an Anti-Corruption Compliance Program in Canada Date: August 14, 2012 Lawyers You Should Know: Henry Chang Original Newsletter(s) this article was published in: International Business
More informationPPG GLOBAL ANTI-CORRUPTION POLICY
PPG GLOBAL ANTI-CORRUPTION POLICY Introduction As a global company operating in over sixty countries, PPG is required to comply with a number of laws and regulations in order to lawfully conduct its business.
More informationPwC Hong Kong and China Forensic Services 10 December 2017
www.pwc.com Hong Kong and China Forensic Services 10 December 2017 Table of Contents Section Overview 1 Practice Overview 2 Selected Citations 3 Selected CV s Hong Kong, Beijing and Shanghai Practice Overview
More informationEXECUTIVE COMPENSATION GROUP ADVISORY DISCLOSURE DEVELOPMENTS: EXECUTIVE COMPENSATION. Ernest W. Torain, Jr. Vedder Price P.C.
From PLI s Online Program FCPA Compliance in High Risk Jurisdictions #20434 6 EXECUTIVE COMPENSATION GROUP ADVISORY DISCLOSURE DEVELOPMENTS: EXECUTIVE COMPENSATION Ernest W. Torain, Jr. Vedder Price P.C.
More informationMATTHEW T. SCHELP. St. Louis, MO office:
MATTHEW T. SCHELP Partner St. Louis, MO office: 314.480.1772 email: matthew.schelp@ Overview A former federal prosecutor, Matt concentrates his practice in the areas of compliance, internal investigations,
More informationANTI-CORRUPTION POLICY
ANTI-CORRUPTION POLICY PURPOSE AND APPLICATION As the Foundation for a Smoke-Free World, Inc. (the Foundation or we ) expands and develops internationally, the Foundation must ensure that all employees
More informationDEPARTMENT OF HEALTH AND HUMAN SERVICES. Office of Inspector General s Use of Agreements to Protect the Integrity of Federal Health Care Programs
United States Government Accountability Office Report to Congressional Requesters April 2018 DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of Inspector General s Use of Agreements to Protect the Integrity
More informationRetail Solutions Inc.
Retail Solutions Inc. Policy Name: Foreign Anti-Corruption Policy Effective Date: April 2012 Next Review Date: April 2013 Policy Sponsor: Peter Rieman Approved By: Jonathan Golovin Purpose The purpose
More informationForeign Corrupt Practices Act. 15 February 2018
Foreign Corrupt Practices Act 15 February 2018 Introduction The Foreign Corrupt Practices Act ( FCPA ), codified at 15 U.S.C. 78dd-1, et seq., has two separate parts. The antibribery provisions prohibit
More informationDEFICIT REDUCTION ACT AND FALSE CLAIMS POLICY INFORMATION FOR All MASSACHUSETTS WORKFORCE MEMBERS
DEFICIT REDUCTION ACT AND FALSE CLAIMS POLICY INFORMATION FOR All MASSACHUSETTS WORKFORCE MEMBERS The Company is committed to preventing health care fraud, waste and abuse and complying with applicable
More informationBalt USA, LLC Anticorruption Policy
I. Introduction Balt USA, LLC is committed to conducting its business ethically and in compliance with all applicable laws and regulations, including the U.S. Foreign Corrupt Practices Act (FCPA) and other
More informationAnti-Bribery & Anti-Corruption Compliance in Russia
Anti-Bribery & Anti-Corruption Compliance in Russia Alex Stolarsky Rechtsanwalt, Director of Legal, Tax and Compliance, Member of the Board, SCHNEIDER GROUP Veronika Kochieva Legal Team Leader, SCHNEIDER
More informationAnti-Bribery and Anti-Corruption Policy
Anti-Bribery and Anti-Corruption Policy Kirkland Lake Gold Ltd. and its subsidiaries (together, Kirkland Lake Gold, the Company, or we ) are committed to honest and ethical conduct. This theme is emphasized
More informationSupplemental Special Advisory Bulletin: Independent Charity. Patients who cannot afford their cost-sharing obligations
Supplemental Special Advisory Bulletin: Independent Charity Patient Assistance Programs I. Introduction Patients who cannot afford their cost-sharing obligations for prescription drugs may be able to obtain
More informationAnti-Bribery and Corruption Policy. Viva Energy Group Limited (ACN )
Anti-Bribery and Corruption Policy Viva Energy Group Limited (ACN 626 661 032) Adopted by the Board on 18 June 2018 1 Introduction and purpose 1.1 Viva Energy Group Limited (together with its subsidiaries
More informationWeb Seminar. Physician Payments in the "Sunshine": Implications of CMS Regulations for Business and the Future of American Health Care.
Web Seminar Physician Payments in the "Sunshine": Implications of CMS Regulations for Business and the Future of American Health Care Featuring James C. Stansel Sidley Austin LLP Meenakshi Datta Sidley
More informationAnti-Bribery and Anti-Corruption Policy
Anti-Bribery and Anti-Corruption Policy New Gold Inc. and its subsidiaries (together, New Gold, the Company, or we ) are committed to honest and ethical conduct. This theme is emphasized in our Code of
More informationThe SEC Whistleblower Law and Pharma Manufacturing in the US and Abroad Neil V. Getnick
Blowing the Whistle on cgmps: the Next Big Challenge for Compliance The SEC Whistleblower Law and Pharma Manufacturing in the US and Abroad Neil V. Getnick PHARMACEUTICAL REGULATORY AND COMPLIANCE CONGRESS
More informationAnti-Corruption and OFAC Policy for Apex International Energy G.P., Apex International Energy L.P. and their Subsidiaries (collectively, the Company )
November 22, 2016 Overview This Anti-Corruption and OFAC Policy (the Policy ) is applicable to Apex International Energy G.P., Apex International Energy L.P. and their subsidiaries (collectively, the Company
More informationEMERGING TRENDS IN LATIN AMERICA
EMERGING TRENDS IN LATIN AMERICA 17 th Annual Pharmaceutical & Medical Device Compliance Congress Colleen Conry Michael Casey Partner, Ropes & Gray LLP Counsel, Ropes & Gray LLP 1 1 October 13, 2016 AGENDA
More informationTitle: Anti-Bribery Policy
Title: Anti-Bribery Policy Approved May 2012 Reviewed September 2016 1 1. Introduction The Bribery Act 2010 (the Act) introduces a new, clearer regime for tackling bribery that applies to all commercial
More informationANTI-CORRUPTION POLICY. 1. Introduction.
ANTI-CORRUPTION POLICY 1. Introduction. Combating Corruption. Tapestry, Inc. and its subsidiaries (collectively, the "Company") operate in a wide range of legal and business environments, many of which
More informationStructuring Specialty Pharmacy Distribution Arrangements in a Turbulent Regulatory Environment Mini Summit XVIII
Structuring Specialty Pharmacy Distribution Arrangements in a Turbulent Regulatory Environment Mini Summit XVIII The 16 th Pharmaceutical Compliance Congress and Best Practices Forum Thursday, October
More informationANTI-FRAUD PLAN INTRODUCTION
ANTI-FRAUD PLAN INTRODUCTION We recognize the importance of preventing, detecting and investigating fraud, abuse and waste, and are committed to protecting and preserving the integrity and availability
More informationALTAIR ENGINEERING INC. FOREIGN CORRUPT PRACTICES ACT POLICY. (Adopted as of August 29, 2012)
ALTAIR ENGINEERING INC. FOREIGN CORRUPT PRACTICES ACT POLICY (Adopted as of August 29, 2012) The U.S. Foreign Corrupt Practices Act of 1977, as amended (the Act or the FCPA ), amended the U.S. federal
More information